Biometric Research Program (BRP)

Skip to Content

NIH, National Cancer Institute, Division of Cancer Treatment and Diagnosis (DCTD)

Biometric Research Program

Contact BRP

Home | Sitemap | Contact BRP

Search this site

Predictive Biomarkers in Phase II/III Clinical Trials

Biomarker Targeted Randomized Design

Biomarker Stratified Randomized Design

Binary Endpoint

Time-to-Event Endpoint

Optimal Two-Stage Designs For Phase II Clinical Trials

Integrated Phase II/III Study

Sample Size Planning for Developing Classifiers Using High Dimensional Data

Design, Monitoring and Analysis of Bayesian Basket Discovery Trials

Bayesian Phase II Single Arm Clinical Trials

Online Sample Size Calculation

Last Updated:

Optimal Two-Stage Designs For Phase II Clinical Trials

Richard Simon, Controlled Clinical Trials 10:1-10, 1989

	Enter probability of accepting poor drug (alpha) [between 0 and 0.3 only]
	Enter probability of rejecting good drug (beta) [between 0 and 0.3 only]
	Enter response probabilty of poor drug (P0) [between 0 and 1]
	Enter response probability of good drug (P1) [P1 should be greater than P0]